Rosa Gini, PhD

Agenzia Regionale di Sanità della Toscana (ARS Toscana), Florence, Italy, Italy

Poster(s):

• (C-237) Assessing the Risk of Angioedema in Adult Sacubitril/Valsartan Users With Heart Failure: Results From a Post-Authorization Safety Study in Seven European Electronic Healthcare Databases
  Tuesday, August 26, 2025

  12:00 PM - 1:30 PM ET

• (A-141) Contribution to the Development of the ATC/DDD Classification System from Italian Working Group on DDD: Assigning a Defined Daily Dose (DDD) to Anti-Angiogenic Drugs (ATC S01LA)
  Sunday, August 24, 2025

  12:00 PM - 1:30 PM ET

• (B-068) Impact of andexanet alfa introduction on mortality and thromboembolic events, before and after Tuscan guidelines, in patients treated with rivaroxaban or apixaban with major bleeding
  Monday, August 25, 2025

  11:30 AM - 1:00 PM ET

• (SLB-036) Investigating Potential Drug-Drug-Interactions Between Sacubitril/Valsartan and Statins and the Risk of Myotoxicity, Hepatotoxicity or Acute Pancreatitis: A Post-Authorisation Safety Study in 7 European Healthcare Databases
  Monday, August 25, 2025

  11:45 AM - 12:45 PM ET

• (B-093) Preliminary results from a European post authorization study to assess the safety of Paxlovid among patients with moderate or severe hepatic or renal impairment
  Monday, August 25, 2025

  11:30 AM - 1:00 PM ET

• (B-257) Preliminary Results from a European Post-Authorization Study to Assess the Safety of Paxlovid in Pregnancy
  Monday, August 25, 2025

  11:30 AM - 1:00 PM ET

• (SLC-053) Risk of Venous Thrombosis With Thrombocytopenia Syndrome After Vaccination With AZD1222: A European VAC4EU Post-Authorisation Safety Study
  Tuesday, August 26, 2025

  12:15 PM - 1:15 PM ET

• (SLA-038) Single and multiple switches, swap and retransitioning among 28,073 biological drug users with inflammatory bowel disease: results from Italian VALORE distributed database network
  Sunday, August 24, 2025

  12:15 PM - 1:15 PM ET